PGR (Progesterone receptor)

P2, N=40, Completed, Beijing Wehand-Bio Pharmaceutical Co., Ltd | Phase classification: P1 --> P2

However, whole-body ⁶⁸Ga-FAPI PET/CT revealed a markedly different disease burden. This case highlights the added diagnostic value of ⁶⁸Ga-FAPI PET/CT in detecting the true extent of ILC, particularly when conventional imaging appears limited.

This study revealed the expression interplay and clinical significance of KIF2A and p53 in breast cancer. The identified association between KIF2A and p53 may provide insights for future research on their roles in breast cancer.

DMPA-associated meningiomas represent a recognizable phenotype within the broader NF2-wildtype/TRAF7-enriched spectrum of benign meningiomas, characterized by chromosomal stability, a shared methylation profile, tumor multiplicity, and regression or stabilization following DMPA cessation. While derived from a small single-institution cohort, these findings provide a molecular framework for understanding progestin-associated meningioma biology, re-interpreting epidemiologic literature, and informing population-level risk stratification.

P1, N=48, Recruiting, Novartis Pharmaceuticals | Active, not recruiting --> Recruiting

P1, N=30, Recruiting, Canadian Cancer Trials Group | Not yet recruiting --> Recruiting

These findings highlight the potential of red blood cell-derived extracellular vesicles as a biocompatible delivery system enabling combined therapy and offering a promising strategy to overcome current limitations in TNBC treatment.

In conclusion, integrating intratumoral, inner peritumoral, and outer peritumoral radiomic features (Rad All model) may provide more reliable predictive performance for postoperative recurrence in HER2-positive breast cancer compared with single-region radiomic models. The combined nomogram incorporating Rad All and clinical risk factors further improves predictive efficacy and may serve as a supplementary tool for clinical decision-making. SHAP analysis enhances model interpretability by identifying key predictive features. However, given the lack of independent external validation, the generalizability of our models needs to be further verified in future prospective multi-center studies.

P3, N=420, Not yet recruiting, Fudan University

P1, N=46, Completed, Ono Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed

P2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026

P=N/A, N=400, Not yet recruiting, IceCure Medical Ltd.